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ABSTRACT
Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory
bone disease, and patients with active or recurrent bone inflammation
at multiple sites are diagnosed with chronic recurrent multifocal
osteomyelitis (CRMO). The Chronic multifocal osteomyelitis (CMO)
mouse model develops IL-1β-driven sterile bone lesions reminiscent
of severe CRMO. The goal of this study was to evaluate the potential
involvement of mast cells in CMO/CRMO. Here, we show that mast
cells accumulate in inflamed tissues from CMO mice and that mast
cell protease Mcpt1 can be detected in the peripheral blood.
A transgenic model of connective tissue mast cell depletion (Mcpt5-
Cre:Rosa26-Stopfl/fl-DTa) was crossed with CMO mice and the
resulting mice (referred to as CMO/MC–) showed a significant delay in
disease onset comparedwith age-matchedCMOmice. At 5-6 months of
age, CMO/MC– mice had fewer bone lesions and immune infiltration
in the popliteal lymph nodes that drain the affected tissues. In bone
marrow-derived mast cell cultures from CMO mice, cytokine
production in response to the alarmin IL-33 was elevated compared
with wild-type cultures. To test the relevance of mast cells to human
CRMO, we tested serum samples from a cohort of healthy controls
and from CRMO patients at diagnosis. Interestingly, mast cell
chymase was elevated in CRMO patients as well as in patients with
oligoarticular juvenile arthritis. Tryptase-positive mast cells were also
detected in bone lesions from CRMO patients and patients with
bacterial osteomyelitis. Together, our results identify mast cells as
cellular contributors to bone inflammation in CMO/CRMOand provide
rationale for further study of mast cells as therapeutic targets.
KEY WORDS: Autoinflammation, Chronic recurrent multifocal
osteomyelitis, Cytokines, Interleukin-1β, Bone disease, CNO
INTRODUCTION
Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory
bone disease (Zhao and Ferguson, 2018). Although some patients
exhibit bone lesions at single sites, most patients develop chronically
active or recurrent bone inflammation at multiple sites, and are then
diagnosed with recurrent multifocal osteomyelitis (CRMO)
(Ferguson et al., 2006; Ferguson and Laxer, 2015; Ferguson and
Sandu, 2012; Hofmann et al., 2016b; Schnabel et al., 2016). CRMO
partially resembles other syndromic autoinflammatory bone diseases,
such as deficiency of the interleukin (IL)-1 receptor antagonist
(DIRA) or Majeed syndrome (Aksentijevich et al., 2009; Ferguson
et al., 2005). CRMO patients with active disease are characterized by
elevated pro-inflammatory cytokines [tumor necrosis factor (TNF)-α,
IL-1β, IL-6 and IL-8] in the serum (Hofmann et al., 2016a), and
reduced IL-10 production in peripheral blood monocytes (Hofmann
et al., 2011). In CRMO patient samples, reduced IL-10 expression
correlates with increased inflammasome expression and activation
(Brandt et al., 2018), leading to increased IL-1β-driven inflammatory
bone loss (Cox and Ferguson, 2018; Hofmann et al., 2015; Zhao and
Ferguson, 2018).
Several key features of severe CRMO are modeled in chronic
multifocal osteomyelitis (CMO) mice (Chitu et al., 2009; Ferguson
et al., 2006). CMO mice carry destabilizing homozygous L98P
mutations in the gene encoding proline-serine-threonine
phosphatase-interacting protein 2 (Pstpip2) (Chitu et al., 2009;
Ferguson et al., 2006). Expression of PSTPIP2 protein is restricted
to hematopoietic progenitors and innate immune cells (Cassel et al.,
2014; Chitu et al., 2009; Liu et al., 2014; Lukens et al., 2014a).
PSTPIP2 suppresses differentiation and the effector function of
macrophages (Chitu et al., 2009, 2005; Tsujita et al., 2013),
neutrophils (Cassel et al., 2014; Lukens et al., 2014a,b; Netea et al.,
2015) and osteoclasts (Chitu et al., 2012). This could be explained
by PSTPIP2 promoting plasma membrane recruitment of negative
regulators of immune cell activation (Itoh et al., 2005; Tsujita et al.,
2006), including PEST protein-tyrosine phosphatases (Chitu et al.,
2012; Drobek et al., 2015; Wu et al., 1988), C-terminal Src kinase
(Csk) (Drobek et al., 2015) and the phosphatidylinositol-3,4,5-
trisphosphate 5-phosphatase SHIP1 (Drobek et al., 2015). These
interactions are enhanced in response to immune cell activation by a
variety of receptors (Chitu et al., 2005; Drobek et al., 2015; Yeung
et al., 1998). PSTPIP2-deficient neutrophils show elevated
responses to inflammatory stimuli (lipopolysaccharide, FcR
capping, crystalline silica) (Cassel et al., 2014; Drobek et al.,
2015), probably caused by increased Src/Ras/Erk (Cloutier and
Veillette, 1996, 1999) and by PI3K/Akt signaling (Huber and
Gibbs, 2015; Rauh et al., 2004). However, PSTPIP2 is also
expressed in other cells, including mast cells (Chitu et al., 2009), but
no functional studies have been reported to date.
Mast cells are specialized innate immune cells residing near
potential portals of entry for pathogens (Tsai et al., 2011). Mast cell
degranulation results in the release of mast cell proteases (chymase,
tryptase), cytokines/chemokines (TNF-α, CXCL1/KC) and
histamine that all promote tissue inflammation, leukocyteReceived 9 April 2019; Accepted 21 July 2019
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recruitment and blood vessel permeability (De Filippo et al., 2013;
Wernersson and Pejler, 2014). Mast cell activation also leads to rapid
production and release of lipid mediators implicated in leukocyte
recruitment and tissue inflammation (Haeggström and Funk, 2011;
Satpathy et al., 2015). Studies using transgenic models of connective
tissue mast cell (CTMC) ablation implicated key roles of mast cells in
allergic skin inflammation and arthritis (Dudeck et al., 2011, 2015;
Schubert et al., 2015). Hence, mast cells and their mediators could
contribute to inflammatory disorders driven by aberrantly activated
innate immune cells, such as found in CMO and CRMO.
In this study, we demonstrate that mast cells accumulate in
inflammatory bone lesions in CMO mice and that genetic ablation
of CTMCs results in delayed onset and reduced severity of the
inflammatory disease. Elevated inflammatory cytokine production
in bone marrow-derived mast cells from CMO mice in response to
IL-33 suggests that mast cells are hyperactive in the CMO model.
Furthermore, we detected mast cell infiltrates in bone tissue lesions
of CRMO patients and the release of mast cell chymase in the serum
of CRMO patients at diagnosis.
RESULTS
Evidence of CTMC activation and role in chronic multifocal
osteomyelitis
To test the relevance of CTMCs to CMO disease pathophysiology,
we collected tail tissues from 5-month-old wild-type (WT) and
Pstpip2cmo/cmo (CMO) mice, when severe multifocal osteomyelitis
develops (Cassel et al., 2014; Ferguson et al., 2006; Lukens et al.,
2014a). Compared with baseline levels of Alcian Blue-stained
CTMCs in WT tail tissue sections, we observed a trend towards
increased CTMCs in CMO tail tissues (Fig. 1A,B). To test for mast
cell activation and mediator release, we collected mouse plasma at
5 months of age and measured the levels of mouse mast cell
protease-1 (MCPT1) by ELISA. MCPT1 levels were significantly
elevated in plasma from CMO mice, as compared with WT animals
(Fig. 1C). These results suggest that CTMCs are present within
inflamed tissues of CMO mice and that mast cell mediators are
produced in this autoinflammatory disease model.
To test the contribution of CTMCs to the development of CMO
disease, we employed a transgenic model that results in constitutive
ablation of CTMCs as a result of diptheria toxin-α expression in
mature CTMCs (Mcpt5-Cre:Rosa26-Stopfl/fl-DTa) (Dudeck et al.,
2011). Both transgenes were crossed with CMO mice (Ferguson
et al., 2006), and backcrossed more than nine generations to produce
CTMC-deficient CMO animals (hereafter referred to as CMO/MC–)
on a uniform Balb/c background. We compared CTMC densities in
ear skin tissue sections from WT, CMO and CMO/MC– mice using
Alcian Blue staining. Compared with WT, we observed elevated
CTMC density in CMO ear skin lesions (Fig. 1D). CMO/MC– ear
skin was largely devoid of CTMCs (Fig. 1D), which also correlated
with reduced inflammation and edema (Fig. S1). These results
Fig. 1. CTMCs promote CMO
disease onset. (A) Representative
images of mast cells detected with
Alcian Blue staining of decalcified tail
tissue sections from 5-month-old WT
and CMO male mice (insets show
magnified view with arrows indicating
mast cells). (B) Quantification of mast
cell density in WT and CMO tail tissue
sections stained with Alcian Blue.
Graph depicts the average mast cell
density per field (mean±s.d., 5 fields/
sample, 3 mice/group). (C) Levels of
MCPT1 were profiled in plasma from
5-month-old male WT (n=3) and
CMO (n=6) mice by ELISA.
(D) Quantification of mast cell
populations in Alcian Blue-stained ear
tissue sections (n=6 per group, 5
fields/mouse). (E) Kaplan–Meier
disease-free survival curve is shown
for WT (n=50), CMO (n=172), and
CMO/MC– (n=42) mice. (F) Average
age of disease onset in CMO (n=40)
and CMO/MC– (n=43) mice. *P<0.05,
**P<0.01, ***P<0.001, ***P<0.001.
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suggest a potential role for CTMC activation in CMO disease and
demonstrate the efficacy of mast cell ablation in the CMO/MC–
model.
To determine the role of CTMCs in CMO disease onset, cohorts
of age-matched CMO and CMO/MC– mice were monitored for
early symptoms of CMO, including tail kinks or deformities in hind
paws. The CMO/MC– cohort showed a significant delay in disease
onset compared with CMO mice, whereas WT mice showed no
disease (Fig. 1E,F). Overall, these results implicate mast cells in
promotion of inflammation in the CMO model.
CTMCdeficiencyprotects againstbonedamage inCMOmice
To test the role of CTMCs in CMO disease progression, tail and paw
tissues were collected from cohorts of male WT, CMO and CMO/
MC– mice at 5 months of age. Analysis of these tissues and
microcomputed tomography (µCT) scans revealed fewer
deformities and bone lesions within the tails and paws of CMO/
MC– mice compared with CMO mice (Fig. 2A). Quantification of
bone density from the µCT scans of six mice from each group
revealed that the CMO/MC– cohort was significantly protected from
the bone loss observed in CMO mice (Fig. 2B). This also correlated
with fewer TRAP-positive osteoclasts in CMO/MC– compared with
CMO tail tissue sections (Fig. S2). These results indicate that
CTMCs promote bone inflammation and the resulting damage by
osteoclasts that are hallmarks of this autoinflammatory disease.
CTMCs promote IL-1β production and immunecell infiltration
in CMO mice
Previous studies of CMO mice revealed a crucial role for elevated
IL-1β production and signaling in this model (Cassel et al., 2014;
Lukens et al., 2014a). To elucidate how CTMCs contribute to IL-1β
production, we prepared tail tissue homogenates from 5-month-old
WT, CMO and CMO/MC– mice and measured IL-1β levels by
ELISA. Consistent with previous studies (Cassel et al., 2014;
Lukens et al., 2014a), CMO tissues had significantly higher IL-1β
levels compared with WT mice, but these levels were largely
normalized in CMO/MC–mice (Fig. 3A). Using immunoblot assays
to separate pro-IL-1β and mature IL-1β, we showed that CMO/MC–
tail tissues had less of the mature form of IL-1β (Fig. 3B). No
differences in serum levels of IL-1β were observed in these mice
(data not shown). These results suggest that CTMCs either
contribute to IL-1β production in the diseased tissues of CMO
mice or promote recruitment of other immune cells that produce
IL-1β in this model.
Prior studies correlated the severity of CMO with the size of
popliteal lymph nodes that ‘drain’ the tail and hind paws (Chitu
et al., 2009; Lukens et al., 2014a). Indeed, popliteal lymph node
mass was elevated in CMO mice compared with WT animals, but
this expansion was reduced in CMO/MC– mice (Fig. 4A). Flow
cytometric analyses of immune cell markers in lymph nodes
revealed that CMO mice had significantly elevated numbers of
Fig. 2. CTMCs promote bone lesion
severity in CMO mice.
(A) Representative images of tails and
hind paw tissues, along with µCT
images of underlying bone lesions in
male 5-month-old WT, CMO and
CMO/MC– mice. (B) Quantification of
bone volume to total volume ratios for
each stack of µCT images of tails and
hind paws for each cohort (n=6 per
group). *P<0.05, **P<0.01.
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FcεRI+/KIT+ mast cells, MHCII+-activated immune cells and a
trend towards increased Ly6G+/Ly6C+ (GR-1) myeloid cells in
lymph nodes compared with either WT or CMO/MC– mice
(Fig. 4B). Together, these results support increased mast cell
density in CMO disease tissues and a role of CTMCs in the
recruitment of immune cells in the inflamed paw and tail tissues of
CMO mice.
Elevated cytokine production in cultured CMO mast cells
Next, we examined potential mast cell activation pathways and
mechanisms to account for mast cell-related defects in CMO mice.
We considered the alarmin IL-33 as a candidate mast cell activator
in the CMO model because of its involvement in sterile
inflammation and high expression of the IL-33 receptor ST2 in
mast cells. We analyzed IL-33 levels and processing in tail tissues
from 5-month-old WT, CMO and CMO/MC– mice. IL-33 levels
were higher in CMO and CMO/MC– tissues compared with WT
mice, consistent with increased levels with inflammation and
disease (Fig. 5A). It is worth noting that the mature form of IL-33
was most abundant in both CMO and CMO/MC– tissues,
suggesting processing by non-CTMC proteases in this model.
To test whether mast cells from CMOmice have cell autonomous
defects in their activation state, we prepared bone marrow-derived
mast cell (BMMC) cultures fromWTand CMOmice. After 4 weeks
in culture in medium supplemented with IL-3 and SCF, we observed
similar levels of KIT and ST2 expression between genotypes
(Fig. 5B). To assess degranulation, we measured β-hexosaminidase
release and observed no significant difference in degranulation in
CMO compared with WT BMMCs that were either untreated or
treated with IL-33 (Fig. 5C). Addition of the calcium ionophore
A23187 triggered degranulation in both genotypes, to a similar
extent (Fig. 5C). We further tested de novo cytokine production in
WT and CMO BMMCs treated with or without IL-33 for 18 h.
Several cytokines or chemokines (GM-CSF, IL-6, MIP-2) were
produced at higher levels in CMO compared with WT BMMCs in
response to IL-33 treatment (Fig. 5D). In contrast, the constitutively
Fig. 3. CTMC deficiency impairs IL-1β production in CMO disease tissue.
(A) Levels of IL-1β detected by ELISA using tail tissue homogenates from
5-month-old maleWT (n=5), CMO (n=18), andCMO/MC–mice (n=9; *P<0.05).
(B) Representative immunoblot detection of pro-IL-1β and mature IL-1β in
homogenates of tail tissues from WT, CMO and CMO/MC– male mice at
5 months of age. The positions of molecular weight markers (left) and pro-IL-1β
and mature IL-1β (right) are shown. The β-actin immunoblot was used as a
loading control.
Fig. 4. Impaired immune cell recruitment to popliteal lymph nodes in CMO/MC– mice. (A) Mean mass of popliteal lymph nodes for WT, CMO, and CMO/
MC– male mice (n=10-20/group). (B) Absolute numbers of mast cells (FcεRI+/KIT+) in popliteal lymph nodes from WT, CMO and CMO/MC– male mice
based on flow cytometry (n=4/group). (C) Absolute numbers of MHCII+ and GR-1+ immune cells in popliteal lymph nodes from WT, CMO and CMO/MC–
male mice based on flow cytometry (n=9-21/group; results pooled from repeated experiments). *P<0.05, **P<0.01.
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produced chemokine MCP-1 was produced at similar levels in WT
and CMO BMMCs (Fig. 5D). Together, these results provide
evidence of a proinflammatory phenotype of CMO mast cells when
triggered by the alarmin IL-33.
Mast cell activation in CRMO patient samples
To test the potential involvement of mast cells in human CRMO, we
screened sera from a previously reported cohort of treatment-naïve,
newly diagnosed CRMO patients, oligoarticular juvenile arthritis
(Oligo JIA) patients, and healthy controls (Hofmann et al., 2016a).
We tested for mast cell chymase by ELISA and detected very low
levels of chymase in 4 of 21 healthy controls, whereas the vast
majority of CRMO patients (17 of 20) exhibited detectable serum
chymase levels (Fig. 6A). No patients in these cohorts had reported
allergies. Of note, a comparable increase in serum chymase levels
was also observed in Oligo JIA patients (Fig. 6A), which is
consistent with a recent study implicating mast cells in arthritis
disease models (Schubert et al., 2015).
To assess mast cell infiltration to inflamed bone tissue, we
performed immunohistochemistry staining of tryptase-positive mast
cells in tissue sections from bone biopsies taken from healthy
controls (osteotomies), CRMO patients, and bacterial osteomyelitis
(OM) patients. Although no mast cells were detected in bone
biopsies from healthy individuals, we detected mast cells in CRMO
lesions, including early CRMO lesions marked by innate immune
infiltrates (Fig. 6B,C). Particularly high mast cell counts were
detected in chronic CRMO lesions marked by coexisting infiltrates
of innate immune cells and lymphocytes (Fig. 6B,C). Mast cell
counts were also increased in bacterial OM bone biopsies compared
with controls (Fig. 6B,C). Together, these results provide evidence
of mast cell involvement in autoinflammation in the bone of patients
with CRMO and related disorders.
DISCUSSION
Studies in CMO mice and related mouse models have provided
insights into the pathophysiology of human CRMO, a rare
autoinflammatory disease. This includes the identification of a
skewed microbiome, increased IL-1β production and aberrantly
activated innate immune cells (Cassel et al., 2014; Chitu et al., 2009,
2012; Lukens et al., 2014a,b). In the study presented here, we show
that mast cells accumulate in CMO lesions and promote the
accumulation of bone inflammation and lesions. By crossing CMO
mice with CTMC-deficient animals (Dudeck et al., 2011), we
provide evidence that CTMCs promote CMO disease onset and
severity. To address cell autonomous mast cell defects in the CMO
model, we show that CMO BMMCs produce elevated levels of
inflammatory cytokines in response to treatment with the alarmin
IL-33, which is elevated in CMO disease tissues. We also translate
these studies to human CRMO by providing evidence of mast cell
infiltrates in bone biopsies from CRMO patients, and elevated levels
of mast cell chymase in the serum of CRMO patients at diagnosis.
Together, these findings implicate mast cells in promoting bone
inflammation in CMO mice and suggest a role for mast cells in the
pathophysiology of CRMO in humans. Our model in Fig. 7 depicts
several candidate mediators from mast cells, including IL-6, that
promote recruitment and activation of the innate immune cells and
osteoclasts that trigger autoinflammation.
A recent study provides evidence of functional crosstalk between
mast cells and osteoclasts, with mast cell degranulation promoting
osteoclast differentiation and activation in bone fracture and
osteoporosis models (Kroner et al., 2017). Mast cell-derived TNF-
α has also been reported to promote bone loss in periodontitis
induced by oral cavity infection with Porphyromonas gingivalis
(Malcolm et al., 2016). Our study also suggests that mast cell
activation promotes osteoclast expansion and bone loss in the CMO
model. It is worth noting that osteoclast differentiation from
immature myeloid cells has been reported in arthritis (Zhang et al.,
2015a), and it will be worth testing whether mast cells contribute to
this process in CMO/CRMO. Our findings that CMO mast cells
release more IL-6 could explain increased osteoclast numbers and
bone loss based on the role of IL-6 in collagen-induced arthritis
models (Tanaka et al., 2014). Mast cell-derived IL-6 has also been
implicated in mobilization of dendritic cell subsets linked to
inflammation (Dawicki et al., 2010). It is worth noting that mast
cells might participate in a bone reparation or remodeling pathway
that is co-opted in the CMO model and that mast cells could have
both positive and negative effects on bone inflammation overall.
Future studies are warranted in order to fully dissect the potential
crosstalk between mast cells, dendritic cells, osteoclasts and other
relevant cell types in CRMO and related diseases.
Because CMO mice are protected from disease when crossed
onto either IL-1R-null or IL-1β-null backgrounds (Cassel et al.,
Fig. 5. Increased cytokine
production by CMO BMMCs treated
with IL-33. (A) Representative
immunoblot detection of pro-IL-33 and
mature IL-33 in homogenates of tail
tissues from WT, CMO and CMO/MC–
male mice at 5 months of age. The
positions of molecular weight markers
(left) and pro-IL-33 and mature IL-33
(right) are shown. The β-actin
immunoblot was used as a loading
control. (B) Representative flow
cytometry histograms of ST2 and KIT
expression in WT and CMO BMMCs.
(C) Mast cell degranulation in WT and
CMO BMMCs following treatment with
or without calcium ionophore (A23187)
or IL-33 for 15 min (n=4/genotype).
(D) Cytokine production for WT and
CMO BMMCs following treatment with
or without IL-33 for 18 h (n=3/
genotype). *P<0.05.
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2014; Lukens et al., 2014a), mast cells could be an important source
of IL-1β in this disease model. Alternatively, the reduced levels of
IL-1β in CMO/MC– mice might be a result of impaired recruitment
of IL-1β-producing immune cells. Indeed, draining lymph nodes
from CMO/MC– mice contained fewer innate immune cells
compared with CMO mice. Mast cell proteases released in
response to activation could also enhance cleavage of pro-IL-1β
in inflamed tissues, based on studies in other models (Caughey,
2007; Dong et al., 2012). Interestingly, chymase is elevated in
serum from CMO mice and CRMO patients at diagnosis. Thus,
chymase could indeed participate in CMO and CRMO
pathophysiology and is worthy of further functional studies.
Previous studies suggested that neutrophils in CMO produce
aberrant levels of IL-1β in an inflammasome-independent manner,
which might be responsible for driving the CMO disease
pathophysiology (Cassel et al., 2014; Lukens et al., 2014b).
Indeed, depletion of neutrophils using a Ly6G antibody protected
CMOmice from bone lesion development (Lukens et al., 2014b). It
is worth noting that granulocytic myeloid-derived suppressor cells
(G-MDSCs) express both Ly6C and Ly6G markers (Ly6Clo/
Ly6Ghi), and are recruited to bone as the main osteoclast precursor
population (Sawant and Ponnazhagan, 2013; Zhang et al., 2015a).
These cells then differentiate into osteoclasts in chronic
inflammatory disorders such as arthritis and bone cancer (Fujii
et al., 2013; Sawant and Ponnazhagan, 2013; Zhang et al., 2015a,b).
Thus, ‘neutrophil’ depletion with inactivating anti-Ly6G antibodies
in CMO mice (Lukens et al., 2014b) might have also depleted
osteoclast precursor G-MDSCs, which would lead to fewer
osteoclasts and reduced bone resorption. Interestingly, MDSC
proliferation has been reported to be mast cell dependent (Hegde
et al., 2015). Further studies using more selective tools to deplete
and phenotype the inflammatory cells in this model are needed to
define CMO disease pathophysiology better.
The identity of potential triggers of CMO disease and restrictions
of the phenotypes to certain tissues remains poorly defined. A
previous study identified a skewed microbiome in CMO mice that
leads to priming of neutrophils to express IL-1β (Lukens et al.,
2014b). Based on the selective loss of CTMCs in our model, with no
effect on mucosal mast cells (Dudeck et al., 2011; Sharma et al.,
2012), there could be mast cell involvement at the interface with a
skewed microbiome but we have not yet tested this. However, future
studies using Cpa3Cre mice, lacking both mucosal and connective
tissue mast cells (Feyerabend et al., 2011), would provide an
improved model to test the overall contribution of mast cells to this
disease. Our findings in this study also identified elevated levels of
mature IL-33 in the tail tissues of diseased CMO and CMO/MC–
mice, and showed that IL-33 might trigger aberrant mast cell
activation in this model. It is worth noting that transgenic mice with
IL-33 overexpression in the myeloid compartment develop severe
neutrophil-driven inflammation in several tissues, including the
paws (Talabot-Ayer et al., 2015). As in CMO mice (Chitu et al.,
2009), elevated proinflammatory cytokines such as IL-1β and IL-6
have been linked to IL-33-driven sterile inflammation (Talabot-
Ayer et al., 2015). It is also noteworthy that levels of IL-33 and
soluble ST2 were elevated in serum of patients with the
autoinflammatory Behcet’s disease (Kim et al., 2013). Further
studies of the IL-33–ST2 axis as a biomarker or therapeutic target in
CMO/CRMO are certainly warranted.
To translate findings from our study of the involvement of mast
cells in murine CMO to CRMO in humans, we stained bone
samples from CRMO patients. Our results demonstrated increased
mast cell populations in CRMO patients. Profiling of CRMO serum
biomarkers highlighted a number of cytokines and chemokines that
were elevated at diagnosis (Hofmann et al., 2016a), several of which
are known to be released by activated human mast cells (Dawicki
et al., 2010; Oldford et al., 2010; Sugitharini et al., 2016). Our
detection of elevated levels of mast cell chymase in sera from most
CRMOpatients provides new evidence of mast cell activation in this
disease. This was also true for Oligo JIA patient sera, suggesting a
common immune mechanism involving mast cells in these diseases.
Of note, chymase can directly promote IL-1β production (Mizutani
Fig. 6. Detection of mast cells and mast cell mediators in CRMO patient
samples. (A) Serum samples from human patients with CRMO (n=20),
oligoarticular JIA patients (n=20) or healthy controls (n=21) were tested for the
levels of mast cell chymase by ELISA. Dot plot depicts individual values with
median and interquartile range overlaid. (B) Representative images of tryptase
staining of bone from healthy controls, early and chronic CRMO patients and
infectious osteomyelitis patients. (C) Percentage of tryptase-positivemast cells
relative to total nucleated cells in the field of view for bone sections from healthy
controls, early and chronic lesions from CRMO patients, and bacterial OM
patients. *P<0.05, **P<0.01.
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et al., 1991), and other mast cell mediators might also contribute to
IL-1β-driven disease in CRMO patients (Hofmann et al., 2015,
2016a). This is also consistent with our findings of elevated mast
cell density in bone tissue sections from CRMO and bacterial OM
patients compared with healthy controls. A parallel study of other
immune cell types was recently reported for this panel of patient
samples, with significant increases in CD14+ monocytes, CD15+
neutrophils, lymphocytes and plasma cells (Brandt et al., 2018).
Future studies are needed to examine the potential mast cell
interactions with these immune cells in CRMO and bacterial OM
disease samples.
In conclusion, we demonstrate a role for mast cells in the
progression of autoinflammatory bone disease using mouse models
and human CRMO patient samples. We show that aberrant mast cell
activation enhances the cycle of IL-1β-driven sterile inflammation
that triggers bone loss in this disease (Fig. 7). Indeed, there is
growing evidence of mast cell involvement in autoinflammation in a
variety of models and diseases (Bonnekoh et al., 2018). This study
provides the rationale to study the effects of mast cell-targeted
therapies in CNO and related autoinflammatory bone diseases.
MATERIALS AND METHODS
Mouse studies
The constitutive CTMC ablation model (Mcpt5-Cre:Rosa-Stopfl/fl-Dta)
(Dudeck et al., 2011) was crossed for 10 generations with Pstpip2cmo/cmo
(CMO) mice (Chitu et al., 2012) to achieve a uniform BALB/cAnPt
background for all (CMO/MC–) mice. All animals were housed at Queen’s
University Animal Care Services under specific pathogen-free conditions.
All procedures were approved by the Queen’s University Animal Care
committee in accordance with Canadian Council on Animal Care
guidelines.
Disease scoring, pharmacological treatments and preparation of
tissue homogenates
Wild-type (WT), CMO and CMO/MC– mice were monitored for the initial
appearance of a tail kink or paw deformity to record the date of disease
onset. For tissue cytokine measurements, equal weights of distal tail
segments and hind paws were snap-frozen, homogenized and assayed for
IL-1β (e-bioscience) using ELISA. To distinguish levels of pro- and mature
forms of IL-1β and IL-33, some homogenates were analyzed by
immunoblot using mouse anti-IL-1β (3A6, Cell Signaling Technology)
and goat anti-IL-33 (R&D Systems); anti-β-actin (Santa Cruz
Biotechnology) served as a loading control.
Lymph node immune profiling
Popliteal lymph nodes from each mouse were collected, weighed and
manually homogenized in PBS-EDTA solution. Cells were counted,
resuspended in PBS containing sodium azide (0.1%) and BSA (0.5%),
and stained with FITC anti-CD117 (c-KIT, BioLegend), PE anti-FcεRI
(BioLegend), FITC anti-I-Ek/RT1-D (MHC II, BioLegend), FITC anti-
Ly6C (BD Biosciences) or PE anti-Ly6G (BD Biosciences). Samples were
analyzed using a cytomics Fc500 (Beckman Coulter), and FlowJo software
(Tree Star), with gating set to exclude dead cells (low forward and side
scatter); isotype control antibodies were used to set threshold values.
Bone marrow-derived mast cell cultures and treatments
Bone marrow-derived mast cell (BMMC) cultures were established from
femoral bone marrow cells in the presence of IL-3 and stem cell factor (SCF)
as described previously (McPherson et al., 2009; Samayawardhena et al.,
2007; Udell et al., 2006). BMMC maturation and ST2 expression were
assessed by staining with KIT (FITC anti-KIT, BioLegend) and ST2 (PE-
Cy7 anti-ST2, BioLegend), and analyzed using a FACS Aria III (Beckman
Coulter). Gating was set to exclude dead cells (low forward and side scatter);
isotype controls were used to set threshold values. Degranulation of
BMMCs was measured upon treatment with or without calcium ionophore
A23187 (1 µM), or IL-33 (10 ng/ml; Peprotech) for 15 min using a
β-hexosaminidase release assay. To measure cytokine production, mature
BMMCs were treated with or without IL-33 (10 ng/ml) for 18 h.
Conditioned medium was collected for cytokine detection using a
multiplex panel of mouse cytokines (mouse high-sensitivity 18-plex
assay, Eve Technologies Inc.).
Microcomputed tomography
Tail and hind paws harvested from male mice at 5 months of age were
analyzed in a Skyscan 1172 high-resolution µCT scanner (Bruker, Milton,
Canada). With the X-ray source at 100 kVp and 100 µA, and the use of a
Fig. 7. Hypothetical model of the potential
crosstalk between mast cell mediators and
cell types implicated in autoinflammation.
Model depicts the effects of mast cell activation
by alarmin IL-33 or other triggers, and the effects
of subsequent mediator release on the
recruitment and activation of innate immune cells
and osteoclasts implicated in promoting IL-1β-
driven sterile bone inflammation. The effects of
IL-6 and other mast cell mediators on these cell
types might promote inflammation in this model
(see text for details). KC, keratinocyte
chemoattractant (CXCL1); LTC4, leukotriene C4;
M-CSF, macrophage colony stimulating factor;
PMN, polymorphonuclear leukocytes; RANKL,
receptor activator of nuclear factor kappa-B
ligand; TNF-a, tumor necrosis factor alpha.
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0.5 mm aluminium filter, each specimen was rotated 360° around the
vertical axis to generate 1200 views in 5 h. The image projections were
reconstructed into digital cross-sections using the Feldkamp algorithm
(Feldkamp et al., 1984) for cone beam CT. The resulting 3D data block
contained 2000×1000×1000 voxels of 13.4 µm, resampled to match the
resolution (28 µm) and data size of the 3D segmented atlas. Down-sampling
of the 3D images was performed because the 2× decrease in voxel size
allowed 8× reductions in the amount of RAM used and image processing
times. Volume fraction data (BV/TV) for serial sections were analyzed with
ImageJ software plugin BoneJ (Doube et al., 2010).
Human CRMO patient serum and bone biopsy analyses
The cohort of CRMO patient serum samples taken at initial diagnosis was
described previously (Hofmann et al., 2016a). Chymase levels were
measured by ELISA (Cusabio) at University Hospital Carl Custav Carus
(Dresden, Germany) in sera from 20 CRMO patients and 21 matched
controls. Patients and controls had no records of allergies in their patient
records, and all patients and/or their legal guardians gave written informed
consent (Ethics Committees at University of Würzburg and University of
Technology Dresden) in accordance with the Declaration of Helsinki
principles (Hofmann et al., 2016a). Formalin-fixed, decalcified and
paraffin-embedded bone biopsy specimens from healthy control
osteotomies (n=2) and patients with bacterial OM (n=3), early CRMO
lesions (n=4) or chronic phase CRMO lesions (n=4) (Brandt et al., 2018)
were stained with an anti-human-tryptase antibody (Abcam, ab2378,
dilution: 1:500) using standard techniques. Nuclei were stained using
hematoxylin and Bluing reagent on the BenchMarkXT staining system
(Ventana Medical Systems/Roche). Slides were scanned on the AxioScan
Z1 (Zeiss, Germany) and quantified using Zen Blue software (Zeiss,
Germany) in 15-25 fields of view (32,188.774 µm2).
Statistical analysis
To compare the three genotypes, we used Kruskal–Wallis nonparametric
testing with multiple comparison testing (GraphPad Prism Software, La
Jolla, California).
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Appendix A. Supplementary Figures 
Fig. S1. Connective tissue mast cell density increases in CMO skin lesions and efficacy of mast 
cell ablation. Representative images of 5 month old WT, CMO and CMO/MC- male mouse 
tissues, including ears (upper panels) and ear tissue sections (lower panels) stained with H&E or 
Alcian blue.  
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Fig. S2. Connective tissue mast cells promote osteoclast accumulation in CMO mice. 
Representative histological images of decalcified tail tissue sections stained with H&E (upper 
panels) and TRAP (lower panels) for male WT, CMO and CMO/MC- mice at 5 months of age 
(arrows indicate TRAP+ osteoclasts).  
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